Hoyoung M. Maeng, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 3B37
- Bethesda, MD 20892
Dr. Maeng’s research focuses on harnessing the immune system to prevent and treat cancer. She believes that the essence of the NIH is "bench-to-bedside and back" exemplified by the vaccines that were invented by the researchers at the NIH and brought to clinical trials at the NIH Clinical Center. She leads the clinical trials team at the Vaccine Branch and is deeply involved in translating the preclinical findings into first-in-human clinical trials using cancer vaccines and other immune-modulatory agents.
Areas of Expertise
1) Cancer vaccines 2) Cancer immunotherapy 3) Early clinical trials 4) Immune escape of cancer 5) Lynch syndrome
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Dr. Maeng's clinical research involves vaccines to harness one's own immune system to prevent and treat cancer including cancers associated with viral infections or hereditary cancer syndromes. She leads the effort in exploring various strategies to broaden cancer treatment options with lower toxicity and improved efficacy at the Vaccine Branch.
Phase I clinical trial of an autologous dendritic cell vaccine against HER2 as a single agent immunotherapy shows safety and preliminary clinical benefit.
Cancer Vaccines-Translational Strategies.
Hoyoung M. Maeng, M.D.
Dr. Maeng graduated from Yonsei University College of Medicine, Seoul, South Korea with an M.D. in 1998. She started her first research project in Yonsei Cancer Center as a medical student where she first developed an interest in translational medicine. She completed her residency in internal medicine followed by a fellowship in hematology and oncology at Severance Hospital, Yonsei University. Further training at the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center as a research fellow in 2005 provided her with a deeper insight into the understanding of viral oncoprotein and cancer. Based on the work done at that time, she was awarded the AACR-MedImmune Fellowship in 2007. After serving at the hospital operated by the National Insurance Corporation of the Korean government as a malignant hematology specialist, she returned to the U.S. to pursue a career as a translational researcher. She then completed her leukemia fellowship at the University of Texas MD Anderson Cancer Center, followed by a fellowship in medical oncology at the NCI.